固执已见
发表于 2025-3-21 18:00:58
书目名称Nuclear Non-Proliferation in International Law - Volume VI影响因子(影响力)<br> http://figure.impactfactor.cn/if/?ISSN=BK0668627<br><br> <br><br>书目名称Nuclear Non-Proliferation in International Law - Volume VI影响因子(影响力)学科排名<br> http://figure.impactfactor.cn/ifr/?ISSN=BK0668627<br><br> <br><br>书目名称Nuclear Non-Proliferation in International Law - Volume VI网络公开度<br> http://figure.impactfactor.cn/at/?ISSN=BK0668627<br><br> <br><br>书目名称Nuclear Non-Proliferation in International Law - Volume VI网络公开度学科排名<br> http://figure.impactfactor.cn/atr/?ISSN=BK0668627<br><br> <br><br>书目名称Nuclear Non-Proliferation in International Law - Volume VI被引频次<br> http://figure.impactfactor.cn/tc/?ISSN=BK0668627<br><br> <br><br>书目名称Nuclear Non-Proliferation in International Law - Volume VI被引频次学科排名<br> http://figure.impactfactor.cn/tcr/?ISSN=BK0668627<br><br> <br><br>书目名称Nuclear Non-Proliferation in International Law - Volume VI年度引用<br> http://figure.impactfactor.cn/ii/?ISSN=BK0668627<br><br> <br><br>书目名称Nuclear Non-Proliferation in International Law - Volume VI年度引用学科排名<br> http://figure.impactfactor.cn/iir/?ISSN=BK0668627<br><br> <br><br>书目名称Nuclear Non-Proliferation in International Law - Volume VI读者反馈<br> http://figure.impactfactor.cn/5y/?ISSN=BK0668627<br><br> <br><br>书目名称Nuclear Non-Proliferation in International Law - Volume VI读者反馈学科排名<br> http://figure.impactfactor.cn/5yr/?ISSN=BK0668627<br><br> <br><br>
草率男
发表于 2025-3-21 22:06:50
Michelle Gallantge research. Today, a crop of biotech startups and dedicated physicians is racing to win regulatory approval for phage therapy before superbugs exhaust the last drug in the medical arsenal. Will they clear the hurdles in time? .978-1-4899-8681-8978-1-4614-0251-0
捐助
发表于 2025-3-22 02:13:40
http://reply.papertrans.cn/67/6687/668627/668627_3.png
Demonstrate
发表于 2025-3-22 07:56:49
Daniel Rietikerge research. Today, a crop of biotech startups and dedicated physicians is racing to win regulatory approval for phage therapy before superbugs exhaust the last drug in the medical arsenal. Will they clear the hurdles in time? .978-1-4899-8681-8978-1-4614-0251-0
Notorious
发表于 2025-3-22 12:42:51
Taymoor M. Pilehvar, Esqge research. Today, a crop of biotech startups and dedicated physicians is racing to win regulatory approval for phage therapy before superbugs exhaust the last drug in the medical arsenal. Will they clear the hurdles in time? .978-1-4899-8681-8978-1-4614-0251-0
Verify
发表于 2025-3-22 15:57:02
http://reply.papertrans.cn/67/6687/668627/668627_6.png
Individual
发表于 2025-3-22 17:07:23
http://reply.papertrans.cn/67/6687/668627/668627_7.png
极肥胖
发表于 2025-3-22 23:03:04
ge research. Today, a crop of biotech startups and dedicated physicians is racing to win regulatory approval for phage therapy before superbugs exhaust the last drug in the medical arsenal. Will they clear the hurdles in time? .978-1-4899-8681-8978-1-4614-0251-0
Rinne-Test
发表于 2025-3-23 02:07:53
Jonathan L. Black-Branchge research. Today, a crop of biotech startups and dedicated physicians is racing to win regulatory approval for phage therapy before superbugs exhaust the last drug in the medical arsenal. Will they clear the hurdles in time? .978-1-4899-8681-8978-1-4614-0251-0
dysphagia
发表于 2025-3-23 06:25:28
Stephen Herzogge research. Today, a crop of biotech startups and dedicated physicians is racing to win regulatory approval for phage therapy before superbugs exhaust the last drug in the medical arsenal. Will they clear the hurdles in time? .978-1-4899-8681-8978-1-4614-0251-0